Cartesian Therapeutics Inc. (RNAC)
RNAC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$6.57
-6.01% on the day
Market cap
$198.8M
Micro cap
Revenue · 2025
$2.8M
-92.8% on 2024
Net income · 2025
-$130.3M
-4658.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | RNAC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2016 |
| SEC CIK | 0001453687 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.8M |
| Net income | -$130.3M |
| Operating income | -$143.4M |
| Net margin | -4658.6% |
| Operating margin | -5127.1% |
| Revenue growth | -92.8% |
| Cash | $125.1M |
| Total assets | $296.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 71.1× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2025-01-10 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-09-29 |
| Latest proxy | DEF 14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 874 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SION | Sionna Therapeutics Inc. | $4.38 | -6.61% | $198.0M |
| UPB | Upstream Bio Inc. | $3.55 | -14.87% | $194.4M |
| ELDN | Eledon Pharmaceuticals Inc. | $2.34 | -4.10% | $190.2M |
| TRDA | Entrada Therapeutics Inc. | $4.86 | -11.64% | $189.2M |
| PRQR | ProQR Therapeutics N.V. | $1.48 | -8.64% | $208.9M |
| AKBA | Akebia Therapeutics Inc. | $0.7700 | -2.56% | $213.4M |
| EVMN | Evommune Inc. | $5.88 | -2.81% | $213.4M |
| LYEL | Lyell Immunopharma Inc. | $7.51 | -9.19% | $184.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier